Showing 2201-2210 of 5623 results for "".
- Cellusion Receives FDA Orphan Drug Designation for CLS001https://modernod.com/news/cellusion-receives-fda-orphan-drug-designation-for-cls001/2482028/Cellusion announced that the FDA has granted orphan drug designation to its regenerative medicine product, “iPS cell-derived corneal endothelial cell substitute,” (CLS001) for the treatment of bullous keratopathy. FDA grants orphan drug designation if the drug
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l
- Ocugen's OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of RP Associated with RHO Mutationshttps://modernod.com/news/ocugens-ocu400-receives-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-rp-associated-with-rho-mutations/2482019/Ocugen announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT designation is a significant accomplishment for the OCU400 clinical develo
- Reichert to Distribute Imaging and Dry Eye Treatment Devices in the United Stateshttps://modernod.com/news/reichert-to-distribute-imaging-and-dry-eye-treatment-devices-in-the-united-states/2482016/Reichert Technologies, a business of AMETEK Inc., announced an exclusive partnership with SBM Sistemi of Italy to distribute SBM’s imaging and dry eye assessment and treatment devices in the United States. Financial terms of the deal were not disclosed. </
- NEI Study Shows How Genes in Retina Get Regulated During Developmenthttps://modernod.com/news/nei-study-shows-how-genes-in-retina-get-regulated-during-development/2482012/Using models of a retina grown in the lab, researchers at the National Eye Institute say they have mapped the 3D organization of genetic material of key developmental stages of human retinal formation. The findings lay a foundation for understanding clinical traits in many eye diseases, and
- UAlbany Scientists Explore New Molecular Tool to Treat Retinal Degenerative Diseasehttps://modernod.com/news/ualbany-scientists-explore-new-molecular-tool-to-treat-retinal-degenerative-disease/2482011/University at Albany scientists at the College of Arts and Sciences’ RNA Institute, in collaboration with a research team from the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences, have received a 4-year, $1.8 million grant from the National Eye
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me
- Ciliatech Releases New Design of Glaucoma Surgical Device CIDhttps://modernod.com/news/ciliatech-releases-new-design-of-glaucoma-surgical-device-cid/2481993/Ciliatech announced the release of a new design of its CID (cilioscleral interpositioning device) following the filing of additional patents strengthening its IP (intellectual property). CID is the unique glaucoma surgical device used in the cilioscleral technique to lower IOP whil
- KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implantshttps://modernod.com/news/keralink-international-provides-25-million-in-seed-funding-to-enable-development-of-bioengineered-corneal-implants/2481970/KeraLink International (KLI) announced $2.5 million in seed funding in Pantheon Vision (PV) to launch the development of a novel advancement to help eradicate corneal blindness in both developed and low- and middle-income countries (LMICs). Pantheon Vision, an early-stage ophthalmic med